AstraZeneca and Heptares Therapeutics entered into a licensing agreement under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialize the adenosine A2A receptor antagonist HTL-1071, a small molecule immuno-oncology candidate.
JOHN CUNNINGHAM was appointed chairman of the Department of Pediatrics at the University of Chicago.
The European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products, granted orphan drug designation to synthetic hypericin, the active pharmaceutical ingredient in SGX301, for the treatment of cutaneous T-cell lymphoma, a rare disease and a class of non-Hodgkin's lymphoma.
SITEMAN CANCER CENTER at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis was awarded an “exceptional” rating, the highest possible, by the NCI, based on a rigorous peer review of Siteman's research programs. Siteman is an NCI-designated Comprehensive Cancer Center.
Health Canada issued a Notice of Compliance with Conditions for Imbruvica (ibrutinib) an oral, once-daily single-agent therapy for the treatment of patients with relapsed or refractory mantle cell lymphoma.
LEHIGH VALLEY HEALTH NETWORK announced it will join the Memorial Sloan Kettering Cancer Alliance.
Teva Parenteral Medicines Recalls Adrucil The FDA published a draft guidance for the pharmaceutical industry to ensure that FDA-regulated medications are continually manufactured under strict quality standards.
Carolyn Mary Kaelin, a surgical oncologist in the Women's Cancers Program at Dana-Farber and director of the Breast Clinic at Brigham and Women's Hospital, died July 28, surrounded by loved ones. Kaelin was 54.
Medicare's Part D program paid significantly higher prices for drugs than either Medicaid or the Veterans Health Administration, a study by Carleton University and Public Citizen found.
After a decade of near-absence from the US market, the AstraZeneca drug Iressa (gefitinib) is back.